A Phase III, Randomised, Double-blind, Multicentre Clinical Study to Compare the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Between SB16 (Proposed Denosumab Biosimilar) and Prolia in Postmenopausal Women With Osteoporosis
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Samsung Bioepis
- 15 Nov 2024 According to the Samsung BioLogics Media Release, announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for two denosumab biosimilars based on clinical data from this study.
- 15 Jun 2024 Results comparing SB16 to reference denosumab in patients with postmenopausal osteoporosis , presented at the 25th Annual Congress of the European League Against Rheumatism
- 27 May 2024 According to Samsung Bioepis media release, data from this trial presented at the European Calcified Tissue Society (ECTS) Congress 2024.